X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-11-20 | KAPA | Kairos Pharma, Ltd. | Yu John S | CEO, COB, 10% | P - Purchase | $1.44 | +4,000 | 5,341,837 | 0% | +$5,760 | ||||||
| DM | 2024-11-19 | RNAC | Cartesian Therapeutics, Inc. | Kurtoglu Metin | CTO | S - Sale+OE | $16.78 | -38,689 | 51,033 | -43% | -$649,030 | |||||
| M | 2024-11-19 | SXTP | 60 Degrees Pharmaceuticals, Inc. | Dow Geoffrey S | Pres, CEO | P - Purchase | $0.91 | +7,000 | 76,225 | +10% | +$6,367 | |||||
| M | 2024-11-19 | ANTX | An2 Therapeutics, Inc. | Readnour Robin Shane | Dir | P - Purchase | $1.07 | +200,000 | 514,788 | +64% | +$213,128 | |||||
| DM | 2024-11-19 | CPRX | Catalyst Pharmaceuticals, Inc. | McEnany Patrick J | Chairman of Board of Directors | S - Sale+OE | $21.23 | -170,845 | 4,478,169 | -4% | -$3,627,259 | |||||
2024-11-19 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $13.95 | -100,000 | 11,565,600 | -1% | -$1,394,960 | ||||||
2024-11-19 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $13.95 | -100,000 | 11,565,600 | -1% | -$1,394,960 | ||||||
| M | 2024-11-19 | BNTC | Benitec Biopharma Inc. | Suvretta Capital Management, LLC | Dir, 10% | P - Purchase | $10.05 | +41,436 | 950,314 | +5% | +$416,616 | |||||
| D | 2024-11-20 | TEVA | Teva Pharmaceutical Industries Ltd | Fox Christine | EVP, Head of U.S. Commercial | S - Sale+OE | $16.87 | -19,388 | 44,104 | -31% | -$327,085 | |||||
| D | 2024-11-19 | PBH | Prestige Consumer Healthcare Inc. | Lombardi Ronald M. | CEO | S - Sale+OE | $82.60 | -10,875 | 320,952 | -3% | -$898,241 | |||||
2024-11-19 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $1.01 | -7,785 | 243,019 | -3% | -$7,863 | ||||||
2024-11-19 | NKTR | Nektar Therapeutics | Wilson Mark Andrew | GC | S - Sale | $1.01 | -6,407 | 218,856 | -3% | -$6,471 | ||||||
2024-11-19 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $1.01 | -16,278 | 832,490 | -2% | -$16,441 | ||||||
2024-11-19 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $22.41 | -27,389 | 6,905,851 | 0% | -$613,826 | ||||||
2024-11-19 | BBIO | Bridgebio Pharma, Inc. | Stephenson Brian C | Secretary, Treasurer, CFO | S - Sale | $22.41 | -4,156 | 93,758 | -4% | -$93,137 | ||||||
| DM | 2024-11-18 | CYRX | Cryoport, Inc. | Shelton Jerrell | Pres, CEO | S - Sale+OE | $6.72 | -150,000 | 722,747 | -17% | -$1,007,820 | |||||
| A | 2024-11-08 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.50 | +280,183 | 245,208,533 | 0% | +$421,535 | |||||
2024-11-20 | ETST | Earth Science Tech, Inc. | Saumat Giorgio R. | CEO, 10% | P - Purchase | $0.17 | +75,102 | 121,787,628 | 0% | +$12,871 | ||||||
| D | 2024-11-18 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | CHRO | S - Sale+OE | $41.14 | -25,000 | 94,018 | -21% | -$1,028,520 | |||||
| D | 2024-11-19 | RNA | Avidity Biosciences, Inc. | Levin Arthur A | Dir | S - Sale+OE | $42.12 | -3,323 | 146,202 | -2% | -$139,973 | |||||
| M | 2024-11-18 | ZBIO | Zenas Biopharma, Inc. | Moulder Leon O Jr | CEO | P - Purchase | $14.89 | +10,000 | 1,843,194 | +1% | +$148,925 | |||||
2024-11-18 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale | $16.38 | -6,190 | 173,470 | -3% | -$101,421 | ||||||
2024-11-18 | SYRS | Syros Pharmaceuticals, Inc. | Stephens Kristin | Chief Development Officer | S - Sale | $0.22 | -36,133 | 0 | -100% | -$7,949 | ||||||
2024-11-18 | SYRS | Syros Pharmaceuticals, Inc. | Roth David | Chief Medical Officer | S - Sale | $0.20 | -12,099 | 0 | -100% | -$2,382 | ||||||
2024-11-19 | SYRS | Syros Pharmaceuticals, Inc. | Quirk Gerald E | Chief Legal, Compliance Offic | S - Sale | $0.22 | -46,657 | 0 | -100% | -$10,321 | ||||||
2024-11-18 | SYRS | Syros Pharmaceuticals, Inc. | Chee Conley | Pres, CEO | S - Sale | $0.20 | -134,797 | 0 | -100% | -$26,932 | ||||||
2024-11-18 | SYRS | Syros Pharmaceuticals, Inc. | Haas Jason | CFO | S - Sale | $0.21 | -137,803 | 0 | -100% | -$28,980 | ||||||
| D | 2024-11-18 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $21.04 | -17,000 | 102,975 | -14% | -$357,680 | |||||
| A | 2024-10-28 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale | $11.31 | -459 | 118,115 | 0% | -$5,190 | |||||
2024-11-19 | ACRS | Aclaris Therapeutics, Inc. | Mehra Anand | Dir | P - Purchase | $2.25 | +666,666 | 710,030 | >999% | +$1,499,999 | ||||||
2024-11-18 | TSVT | 2Seventy Bio, Inc. | Maus Marcela V. | Dir | S - Sale | $3.38 | -3,900 | 23,752 | -14% | -$13,182 | ||||||
| M | 2024-11-18 | ANTX | An2 Therapeutics, Inc. | Zakrzewski Joseph S | Dir | P - Purchase | $1.00 | +25,000 | 529,079 | +5% | +$25,046 | |||||
2024-11-19 | ESPR | Esperion Therapeutics, Inc. | Warren Eric | Chief Commercial Officer | S - Sale | $2.17 | -197 | 162,355 | 0% | -$427 | ||||||
2024-11-18 | IRWD | Ironwood Pharmaceuticals Inc | Davis Andrew | SVP, Chief Business Officer | S - Sale | $4.08 | -5,360 | 284,685 | -2% | -$21,869 | ||||||
2024-11-18 | IRWD | Ironwood Pharmaceuticals Inc | Emany Sravan Kumar | SVP, COO, CFO | S - Sale | $4.08 | -11,001 | 309,572 | -3% | -$44,884 | ||||||
2024-11-19 | NVCT | Nuvectis Pharma, Inc. | Poradosu Enrique | Chief Science, Business Off | P - Purchase | $4.99 | +2,000 | 1,506,319 | 0% | +$9,980 | ||||||
| M | 2024-11-15 | SKYE | Skye Bioscience, Inc. | Diep Tuan Tu | Chief Development Officer | S - Sale | $4.99 | -19,574 | 82,259 | -19% | -$97,722 | |||||
2024-11-19 | SVRA | Savara Inc | McCracken Joseph S | Dir | P - Purchase | $2.95 | +20,000 | 210,837 | +10% | +$59,072 | ||||||
| D | 2024-11-15 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale+OE | $27.73 | -9,061 | 74,158 | -11% | -$251,274 | |||||
| M | 2024-11-15 | SKYE | Skye Bioscience, Inc. | Arsenault Kaitlyn | CFO | S - Sale | $4.99 | -43,396 | 166,342 | -21% | -$216,652 | |||||
| D | 2024-11-15 | MNKD | Mannkind Corp | Binder Steven B. | Dir | S - Sale+OE | $6.76 | -67,539 | 1,075,026 | -6% | -$456,564 | |||||
| M | 2024-11-15 | SKYE | Skye Bioscience, Inc. | Dhillon Punit | CEO | S - Sale | $4.99 | -82,910 | 339,166 | -20% | -$413,925 | |||||
| M | 2024-11-15 | SKYE | Skye Bioscience, Inc. | Grayson Paul A. | Dir | S - Sale | $4.99 | -86,551 | 259,701 | -25% | -$432,061 | |||||
| D | 2024-11-19 | ACAD | Acadia Pharmaceuticals Inc | Teehan Brendan | EVP, COO, Head of Commercial | S - Sale+OE | $16.81 | -10,329 | 62,105 | -14% | -$173,630 | |||||
| D | 2024-11-19 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale+OE | $16.81 | -4,073 | 19,863 | -17% | -$68,467 | |||||
| D | 2024-11-19 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $16.81 | -10,259 | 53,302 | -16% | -$172,454 | |||||
2024-11-19 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $9.68 | -1,775 | 181,373 | -1% | -$17,190 | ||||||
| D | 2024-11-18 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $9.26 | -14,400 | 266,598 | -5% | -$133,294 | |||||
| D | 2024-11-18 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | Chief Development Officer | S - Sale+OE | $9.26 | -7,192 | 89,980 | -7% | -$66,573 | |||||
| D | 2024-11-18 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | Chief Medical Officer | S - Sale+OE | $9.26 | -8,077 | 94,199 | -8% | -$74,766 | |||||
2024-11-15 | PTGX | Protagonist Therapeutics, Inc | Molina Arturo Md | Chief Medical Officer | S - Sale | $40.98 | -1,906 | 46,444 | -4% | -$78,108 | ||||||
| D | 2024-11-15 | IRON | Disc Medicine, Inc. | Savage William Jacob | Chief Medical Officer | S - Sale+OE | $59.64 | -9,158 | 40,405 | -18% | -$546,153 | |||||
2024-11-19 | ETST | Earth Science Tech, Inc. | Saumat Giorgio R. | CEO, 10% | P - Purchase | $0.15 | +195,844 | 121,712,526 | 0% | +$29,421 | ||||||
| D | 2024-11-15 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $87.94 | -27,000 | 188,113 | -13% | -$2,374,479 | |||||
| D | 2024-11-18 | DAWN | Day One Biopharmaceuticals, Inc. | Bender Jeremy | CEO | S - Sale+OE | $13.21 | -10,554 | 1,717,215 | -1% | -$139,420 | |||||
| D | 2024-11-18 | DAWN | Day One Biopharmaceuticals, Inc. | Blackman Samuel C. | HEAD OF R, D | S - Sale+OE | $13.21 | -2,206 | 2,064,015 | 0% | -$29,142 | |||||
| D | 2024-11-18 | DAWN | Day One Biopharmaceuticals, Inc. | Dubow Adam | GC | S - Sale+OE | $13.21 | -3,165 | 32,162 | -9% | -$41,810 | |||||
2024-11-18 | RVNC | Revance Therapeutics, Inc. | Hollander David | CMO, Global Therapeutics Lead | S - Sale | $4.17 | -3,908 | 104,945 | -4% | -$16,296 | ||||||
| M | 2024-11-15 | VTVT | Vtv Therapeutics Inc. | Sekhri Paul J | Pres, CEO, Exec Chairperson | P - Purchase | $16.76 | +5,000 | 5,000 | New | +$83,812 | |||||
| D | 2024-11-18 | DAWN | Day One Biopharmaceuticals, Inc. | York Charles N II | COO, CFO, Secretary | S - Sale+OE | $13.21 | -2,602 | 240,133 | -1% | -$34,373 | |||||
| D | 2024-11-18 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $359.21 | -10,000 | 0 | -100% | -$3,592,071 | |||||
2024-11-15 | RMTI | Rockwell Medical, Inc. | Ravich Mark H | Dir | S - Sale | $2.35 | -29,991 | 123,701 | -20% | -$70,379 | ||||||
| D | 2024-11-18 | MCRB | Seres Therapeutics, Inc. | Desrosier Thomas | GC, EVP | S - Sale+OE | $0.54 | -878 | 135,192 | -1% | -$475 | |||||
| D | 2024-11-18 | MCRB | Seres Therapeutics, Inc. | Von Moltke Lisa | See Remarks | S - Sale+OE | $0.54 | -977 | 32,415 | -3% | -$528 | |||||
2024-11-15 | AMRX | Amneal Pharmaceuticals, Inc. | Daly Jason B. | SVP, GC | S - Sale | $8.61 | -43,657 | 13,665 | -76% | -$375,887 | ||||||
| D | 2024-11-18 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $50.55 | -5,000 | 401,622 | -1% | -$252,750 | |||||
| D | 2024-11-18 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | CEO, Pres | S - Sale+OE | $0.54 | -2,505 | 170,389 | -1% | -$1,355 | |||||
| D | 2024-11-18 | MCRB | Seres Therapeutics, Inc. | Young Teresa L. | See Remarks | S - Sale+OE | $0.54 | -735 | 90,404 | -1% | -$398 | |||||
| M | 2024-11-15 | NAMS | Newamsterdam Pharma Co N.V. | Forgrowth Nap B.V. | 10% | S - Sale | $25.07 | -41,803 | 11,778,760 | 0% | -$1,047,876 | |||||
| D | 2024-11-18 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R. | See Remarks | S - Sale+OE | $0.54 | -927 | 77,770 | -1% | -$501 | |||||
2024-11-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Altshuler David | EVP, Chief Scientific Officer | S - Sale | $478.56 | -15 | 25,813 | 0% | -$7,178 | ||||||
| M | 2024-11-15 | IRD | Opus Genetics, Inc. | Magrath George | CEO | P - Purchase | $1.01 | +100,000 | 492,950 | +25% | +$101,158 | |||||
2024-11-18 | KURA | Kura Oncology, Inc. | Ford Kathleen | COO | S - Sale | $16.03 | -526 | 23,184 | -2% | -$8,434 | ||||||
2024-11-18 | ASMB | Assembly Biosciences, Inc. | White Nicole S | Chief Manufacturing Officer | S - Sale | $16.29 | -40 | 11,871 | 0% | -$652 | ||||||
| D | 2024-11-18 | PBH | Prestige Consumer Healthcare Inc. | Lombardi Ronald M. | CEO | S - Sale+OE | $82.56 | -82,237 | 320,952 | -20% | -$6,789,764 | |||||
2024-11-18 | ASRT | Assertio Holdings, Inc. | Mason Heather L | Dir | P - Purchase | $0.80 | +75,000 | 287,650 | +35% | +$60,000 | ||||||
| D | 2024-11-14 | MTEM | Molecular Templates, Inc. | Biotech Target N V | 10% | S - Sale+OE | $0.66 | -1,279,820 | 0 | -100% | -$845,833 | |||||
2024-11-18 | ANTX | An2 Therapeutics, Inc. | Easom Eric | CEO | P - Purchase | $1.00 | +50,000 | 1,361,012 | +4% | +$49,970 | ||||||
| D | 2024-11-14 | CRMD | Cormedix Inc. | Hurlburt Elizabeth | EVP | S - Sale+OE | $11.18 | -140,027 | 45,397 | -76% | -$1,565,670 | |||||
| D | 2024-11-18 | DYN | Dyne Therapeutics, Inc. | Incerti Carlo | Dir | S - Sale+OE | $28.73 | -16,500 | 0 | -100% | -$474,045 | |||||
| M | 2024-11-14 | RNAC | Cartesian Therapeutics, Inc. | Springer Timothy A | Dir, 10% | P - Purchase | $17.07 | +431,940 | 9,316,199 | +5% | +$7,373,527 | |||||
| DM | 2024-11-14 | RNAC | Cartesian Therapeutics, Inc. | Kurtoglu Metin | CTO | S - Sale+OE | $17.46 | -82,368 | 51,033 | -62% | -$1,438,038 | |||||
| DM | 2024-11-14 | RNAC | Cartesian Therapeutics, Inc. | Miljkovic Milos | Chief Medical Officer | S - Sale+OE | $16.50 | -55,000 | 18,273 | -75% | -$907,533 | |||||
| DM | 2024-11-14 | RNAC | Cartesian Therapeutics, Inc. | Jewell Christopher M | Chief Scientific Officer | S - Sale+OE | $16.79 | -52,115 | 25,940 | -67% | -$875,042 | |||||
| M | 2024-11-14 | TNGX | Tango Therapeutics, Inc. | Rothenberg Mace | Dir | P - Purchase | $3.70 | +20,000 | 31,250 | +178% | +$74,000 | |||||
| DM | 2024-11-14 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale+OE | $10.29 | -69,226 | 128,669 | -35% | -$712,621 | |||||
2024-11-14 | VNDA | Vanda Pharmaceuticals Inc. | Mitchell Stephen Ray | Dir | S - Sale | $5.17 | -5,000 | 44,857 | -10% | -$25,863 | ||||||
2024-11-14 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | Dir | S - Sale | $33.10 | -782 | 847,316 | 0% | -$25,884 | ||||||
| M | 2024-10-28 | BIOE | Bio Essence Corp | Yan Yin | CEO, 10% | S - Sale | $1.41 | -323,845 | 82,124 | -80% | -$455,192 | |||||
2024-11-18 | DYN | Dyne Therapeutics, Inc. | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $28.20 | -2,735 | 95,833 | -3% | -$77,127 | ||||||
2024-11-18 | DYN | Dyne Therapeutics, Inc. | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $28.20 | -2,856 | 137,519 | -2% | -$80,539 | ||||||
2024-11-18 | VRNA | Verona Pharma Plc | Ebsworth David R | Dir | P - Purchase | $4.44 | +20,000 | 940,003 | +2% | +$88,800 | ||||||
2024-11-15 | ANIP | Ani Pharmaceuticals Inc | Mutz Christopher | HEAD OF RARE DISEASE | S - Sale | $57.70 | -6,500 | 76,777 | -8% | -$375,050 | ||||||
2024-11-18 | SVRA | Savara Inc | Ramsay David A | Dir | P - Purchase | $2.88 | +100,000 | 2,323,642 | +4% | +$287,600 | ||||||
2024-11-15 | NVCT | Nuvectis Pharma, Inc. | Bentsur Ron | COB, CEO, 10% | P - Purchase | $4.92 | +20,000 | 3,266,424 | +1% | +$98,400 | ||||||
| D | 2024-11-14 | PRAX | Praxis Precision Medicines, Inc. | Nemiroff Alex | GC, Secretary | S - Sale+OE | $80.20 | -8,239 | 10,301 | -44% | -$660,827 | |||||
| D | 2024-11-14 | PRAX | Praxis Precision Medicines, Inc. | Mastrocola Lauren | Principal Accounting Officer | S - Sale+OE | $81.78 | -5,188 | 5,613 | -48% | -$424,318 | |||||
2024-11-15 | WVE | Wave Life Sciences Ltd. | Bolno Paul | Pres, CEO | S - Sale | $14.32 | -51,234 | 217,351 | -19% | -$733,671 | ||||||
2024-11-14 | EQ | Equillium, Inc. | Keyes Jason A | CFO | S - Sale | $0.70 | -10,000 | 121,633 | -8% | -$7,000 | ||||||
| D | 2024-11-14 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale+OE | $47.10 | -2,500 | 2,426 | -51% | -$117,752 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |